Evidence map›Paper›PMID 33785743›Full record

Trial reportNature communications2021

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.

Prasanna Jagannathan, Jason R Andrews, Hector Bonilla, Haley Hedlin, Karen B Jacobson, Vidhya Balasubramanian, Natasha Purington, Savita Kamble, Christiaan R de Vries, Orlando Quintero and 17 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04331899 (A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a), which is not on this map. Cited by 101 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 6 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04331899 phase2completednot on this map

A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19

TypeinterventionalSponsorStanford UniversityRan2020 to 2021Enrolled120ConditionsCOVID-19ArmsPeginterferon Lambda-1a, Placebo
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 6 syntheses or guidelines pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Early Treatment with Pegylated Interferon Lambda for Covid-19.The New England journal of medicine · 2023
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 1 country.

Prasanna JagannathanDepartment of Medicine, Stanford University, Stanford, CA, USA. prasj@stanford.edu.ORCID 0000-0001-6305-758X
Jason R Andrews *Department of Medicine, Stanford University, Stanford, CA, USA.
Hector Bonilla *Department of Medicine, Stanford University, Stanford, CA, USA.
Haley Hedlin *Quantitative Sciences Unit, Stanford University, Stanford, CA, USA.ORCID 0000-0002-0757-7959
Karen B JacobsonDepartment of Medicine, Stanford University, Stanford, CA, USA.
Vidhya BalasubramanianQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Natasha PuringtonQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Savita KambleStanford Center for Clinical Research, Stanford University, Stanford, CA, USA.
Christiaan R de VriesDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-4667-5973
Orlando QuinteroDepartment of Medicine, Stanford University, Stanford, CA, USA.
Kent FengStanford Center for Clinical Research, Stanford University, Stanford, CA, USA.ORCID 0000-0002-7949-9531
Catherine LeyDepartment of Medicine, Stanford University, Stanford, CA, USA.
Dean WinslowDepartment of Medicine, Stanford University, Stanford, CA, USA.
Jennifer NewberryDepartment of Emergency Medicine, Stanford University, Stanford, CA, USA.
Karlie EdwardsDepartment of Medicine, Stanford University, Stanford, CA, USA.
Colin HislopDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Ingrid ChoongDepartment of Pediatrics, Stanford University, Stanford, CA, USA.
Yvonne MaldonadoEiger BioPharmaceuticals, Palo Alto, CA, USA.
Jeffrey GlennDepartment of Medicine, Stanford University, Stanford, CA, USA.
Ami BhattDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-8099-2975
Catherine BlishDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-6946-7627
Taia WangDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3894-685X
Chaitan KhoslaChEM-H, Stanford University, Stanford, CA, USA.
Benjamin A PinskyDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-8751-4810
Manisha DesaiQuantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Julie ParsonnetDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0001-7342-5366
Upinder SinghDepartment of Medicine, Stanford University, Stanford, CA, USA. usingh@stanford.edu.
Stanford University · USCenter for Clinical Research (United States) · USStanford Medicine · USEiger Biopharmaceuticals (United States) · US

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Computational models of naturally acquired immunity to falciparum malariaU01AI150741 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BUTTE, ATUL J, GREENHOUSE, BRYAN R · 2020 to 2024
$7.4M
Global Epidemiology of Infectious DiseasesT32AI052073 · NIAID · STANFORD UNIVERSITY · PI Angelle Desiree LaBeaud, Stephen Patrick Luby · 2003 to 2026
$4.2M
Stanford TRANSFORM I2T ProgramR25AI147369 · NIAID · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW, SINGH, UPINDER · 2019 to 2023
$1.8M
Immunization against Pf bacteriophage in Pseudomonas aeruginosa infectionK08AI151089 · NIAID · STANFORD UNIVERSITY · PI DE VRIES, CHRISTIAAN ROBERT · 2021 to 2021
$162k
NCATS NIH HHS UL1 TR001085NCATS NIH HHS UL1 TR003142NIAID NIH HHS K08 AI151089NIAID NIH HHS R25 AI147369NIAID NIH HHS T32 AI052073NIAID NIH HHS U01 AI150741NIAID NIH HHS U01 AI150741-01S1NIAID NIH HHS U19 AI057229SU | School of Medicine, Stanford University (Stanford School of Medicine, Stanford University) Anonymous Donors
6 · The paper itself

Abstract

Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19). We conducted a randomized, single-blind, placebo-controlled trial (NCT04331899) in 120 outpatients with mild to moderate COVID-19 to determine whether a single, 180 mcg subcutaneous dose of Peginterferon Lambda-1a (Lambda) within 72 hours of diagnosis could shorten the duration of viral shedding (primary endpoint) or symptoms (secondary endpoint). In both the 60 patients receiving Lambda and 60 receiving placebo, the median time to cessation of viral shedding was 7 days (hazard ratio [HR] = 0.81; 95% confidence interval [CI] 0.56 to 1.19). Symptoms resolved in 8 and 9 days in Lambda and placebo, respectively, and symptom duration did not differ significantly between groups (HR 0.94; 95% CI 0.64 to 1.39). Both Lambda and placebo were well-tolerated, though liver transaminase elevations were more common in the Lambda vs. placebo arm (15/60 vs 5/60; p = 0.027). In this study, a single dose of subcutaneous Peginterferon Lambda-1a neither shortened the duration of SARS-CoV-2 viral shedding nor improved symptoms in outpatients with uncomplicated COVID-19.

Indexed as

COVID-19 Drug TreatmentAdultAgedAntiviral AgentsCOVID-19FemaleHumansInjections, SubcutaneousInterferon LambdaInterleukinsMaleMiddle AgedOutpatientsPolyethylene GlycolsSARS-CoV-2Single-Blind MethodAntiviral AgentsInterferon LambdaInterleukinspeginterferon lambda-1aPolyethylene Glycols

Identifiers

PMID33785743
PMCPMC8009873
OpenAlexW3142505488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.